Advertisement

Drugs & Therapy Perspectives

, Volume 31, Issue 11, pp 378–384 | Cite as

Delamanid in multidrug-resistant tuberculosis: a guide to its use in the EU

  • Katherine A. Lyseng-WilliamsonEmail author
  • Hannah A. Blair
  • Lesley J. Scott
Adis Drug Q&A
  • 84 Downloads

Abstract

Oral delamanid (Deltyba®) is a useful addition to the treatment options currently available to treat patients with multidrug-resistant tuberculosis (MDR-TB). In the EU, it is indicated for use as part of an appropriate combination regimen in adults with MDR-TB when an effective treatment regimen cannot otherwise be composed due to resistance or tolerability. It exhibits potent antitubercular activity against drug-susceptible and -resistant strains of Mycobacterium tuberculosis. In a 3-month randomized control trial (2 months treatment + 1 month follow-up) in adults with MDR-TB, delamanid 100 mg twice daily + an optimized background regimen (OBR) improved 2-month sputum culture conversion rates to a significantly greater extent than placebo + OBR. In consecutive extension and follow-up studies, treatment with delamanid for ≥6 to 8 months was associated with higher rates of favourable outcomes and lower rates of unfavourable outcomes than treatment for ≤2 months. Delamanid was generally well tolerated in patients with MDR-TB. To reduce the potential risk of QT interval prolongation with delamanid, recommendations regarding monitoring and precautionary measures should be followed.

Keywords

Isoniazid Moxifloxacin Capreomycin Successful Treatment Outcome Effective Treatment Regimen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The review was updated from Drugs 2015;75(1):91–100 [27], and was reviewed by: N. Cebotarenco, Coalition for Rational and Safe Use of Medicines (CoRSUM), Chişinău, Republic of Moldova; I. D. Olaru, Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany, S. Saluja, Saran Ashram Hospital, Dayalbagh, Agra, India; J-P. Zellweger, Swiss Lung Association, Berne, Switzerland. During the peer review process, the manufacturer of delamanid was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with ethical standards

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

K A. Lyseng-Williamson, H. A. Blair and L. J. Scott are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.

References

  1. 1.
    Lange C, Abubakar I, Alffenaar JW, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J. 2014;44(1):23–63.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Global tuberculosis report 2014. Geneva: World Health Organization; 2014.Google Scholar
  3. 3.
    Zumla AI, Gillespie SH, Hoelscher M, et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis. 2014;14(4):327–40.CrossRefPubMedGoogle Scholar
  4. 4.
    Matteelli A, Roggi A, Carvalho ACC. Extensively drug-resistant tuberculosis: epidemiology and management. Clin Epidemiol. 2014;6(1):111–8.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Sotgiu G, Migliori GB. Facing multi-drug resistant tuberculosis. Pulm Pharmacol Ther. 2015;32:144–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Olaru ID, von Groote-Bidlingmaier F, Heychendorf J, et al. Novel drugs against tuberculosis: a clinician’s perspective. Eur Respir J. 2015;45(4):1119–31.CrossRefPubMedGoogle Scholar
  7. 7.
    Deltyba (delamanid) 50 mg film-coated tablets: summary of product characteristics. London: European Medicines Agency; 2014.Google Scholar
  8. 8.
    Deltyba (delamanid): public assessment report. London: European Medicines Agency; 2014.Google Scholar
  9. 9.
    Hurdle JG, Lee RB, Budha NR, et al. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J Antimicrob Chemother. 2008;62(5):1037–45.PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3(11):e466.PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Shimokawa Y, Sasahara K, Yoda N, et al. Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro. Biol Pharm Bull. 2014;37(11):1727–35.CrossRefPubMedGoogle Scholar
  12. 12.
    Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366(23):2151–60.CrossRefPubMedGoogle Scholar
  13. 13.
    Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2013;41(6):1393–400.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Wells CD, Gupta R, Hittel N, et al. Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid. Eur Respir J. 2015;45(5):1498–501.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Gupta R, Geiter LJ, Wells CD, et al. Delamanid for extensively drug-resistant tuberculosis. New Engl J Med. 2015;373(3):291–2.CrossRefPubMedGoogle Scholar
  16. 16.
    Shimokawa Y, Sasahara K, Koyama N, et al. Metabolic mechanism of delamanid, a new anti-tuberculosis drug, in human plasma. Drug Metab Dispos. 2015;43(8):1277–83.CrossRefPubMedGoogle Scholar
  17. 17.
    Sasahara K, Shimokawa Y, Hirao Y, et al. Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans; importance of albumin metabolism in vivo. Drug Metab Dispos. 2015;43(8):1267–76.CrossRefPubMedGoogle Scholar
  18. 18.
    The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance. Geneva: World Health Organization; 2014.Google Scholar
  19. 19.
    Brigden G, Nyang’wa B-T, du Cros P, et al. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ. 2014;92(1):68–74.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Diacon AH, Von Groote-Bidlingmaier F, Donald PR. Delamanid, a new 6-nitro-2,3-dihydroimidazo[2,1-b]oxazole for the management of tuberculosis resistant to at least isoniazid and rifampicin. Expert Opin Orphan Drugs. 2014;2(1):87–94.CrossRefGoogle Scholar
  21. 21.
    US National Institutes of Health. ClinicalTrials.gov. 2015. http://www.clinicaltrials.gov/. Accessed 23 Sep 2015.
  22. 22.
    Wang H, Zhang X, Bai Y, et al. Comparative efficacy and acceptability of five anti-tubercular drugs in tretament of multidrug resistant tuberculosis: a network meta-analysis. J Clin Bioinforma. 2015;5:5.PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Lessem E, Cox H, Daniels C, et al. Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives. In J Infect Dis. 2015;32:56–60.Google Scholar
  24. 24.
    Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2014.Google Scholar
  25. 25.
    Hafkin J, Frias M, Hesseling A, et al. Pharmacokinetics and safety of delamanid in children ages 6–17 years with MDR TP [poster no. A-960]. In: Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC)/International Congress of Chemotherapy and Infection (ICC); 2015.Google Scholar
  26. 26.
    Diel R, Hittlel N, Schaberg T. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany. Respir Med. 2015;109(5):632–41.CrossRefPubMedGoogle Scholar
  27. 27.
    Blair HA, Scott LJ. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis. Drugs. 2015;75(1):91–100.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Katherine A. Lyseng-Williamson
    • 1
    Email author
  • Hannah A. Blair
    • 1
  • Lesley J. Scott
    • 1
  1. 1.SpringerAucklandNew Zealand

Personalised recommendations